Evidence-based personas put behaviour at the centre of customer intelligence

Tern plc

Personas are useful when they help a business understand how people think, decide and act. They are less useful when they simply create a polished version of what a customer might say. That distinction is becoming more important as artificial intelligence makes it easier to generate convincing customer profiles at speed.

Synthetic personas can appear highly realistic. They can answer questions, react to messages and simulate preferences. This makes them useful for quick testing, creative development and early exploration. The risk is that they may reflect what a model assumes a person would say rather than what real people are likely to do.

Evidence-based personas take a different approach. They are built from real-life data and behavioural signals, with synthetic data used to improve and optimise the model. This matters because commercial decisions need more than plausible language. They need insight into behaviour, timing, barriers, motivations and likely action.

Synthetic personas focus mainly on what people say. Evidence-based personas focus on what people do. That makes them more relevant when decisions carry greater risk, when audiences are complex, or when timing matters. In sectors such as healthcare and life sciences, where customer behaviour can be shaped by regulation, professional context and patient need, a stronger evidence base can improve the quality of decision-making.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Tern plc raises £450,000 in share placing ahead of AIM admission

Tern plc has raised £450,000 through a placing and outlined expected admission timing and updated voting rights.

Search